Young-Ki Lee and colleagues have found that subcutaneous administration of erythropoietin is associated with an increased risk of access failure compared with intravenous administration.

The analysis included 58 hemodialysis patients who had been receiving stable doses of recombinant human erythropoietin ... had undergone a 3-week run-in of subcutaneous darbepoetin alfa, they ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...